Want to join the conversation?
$CELG said overall survival, a key secondary endpoint, showed no benefit with REVLIMID. Based on these results, $CELG does not currently plan to seek approval for this. REMARC evaluated maintenance therapy with REVLIMID versus placebo in diffuse large B-cell lymphoma patients on first-line rituximab plus CHOP chemotherapy induction therapy.
$BA won a $22 billion deal from SpiceJet, their largest order from an Indian airline.
$FB stock remained in the green territory after Raymond James upgraded shares to strong buy from outperform, on expectations that overall 4Q16 ad spending was strong.
$ARRY Good day for the stock, jumped 7%. Great gains !
2017 was supposed to be another record year for automotive industry. Still, $F Ford thinks its profit will dip in 2017..!!
$KKR to buy Hitachi’s power tool unit Hitachi Koki for $1.3 billion. Looks like KKR & Co is going strong in Japan! Remember when it bought Calsonic Kansei a while back?